Pacific Sun Financial Corp Lowers Holdings in VanEck Biotech ETF (NASDAQ:BBH)

Pacific Sun Financial Corp cut its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 2.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,667 shares of the company’s stock after selling 150 shares during the period. Pacific Sun Financial Corp owned approximately 0.22% of VanEck Biotech ETF worth $1,005,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Mather Group LLC. purchased a new position in VanEck Biotech ETF during the 2nd quarter valued at $46,000. Hyman Charles D acquired a new stake in shares of VanEck Biotech ETF during the second quarter worth about $202,000. Northwestern Mutual Wealth Management Co. lifted its position in VanEck Biotech ETF by 5.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock valued at $4,096,000 after purchasing an additional 1,334 shares during the period. Atlas Capital Advisors LLC purchased a new stake in shares of VanEck Biotech ETF in the second quarter worth about $960,000. Finally, Truist Financial Corp grew its stake in shares of VanEck Biotech ETF by 3.8% during the 2nd quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after purchasing an additional 100 shares during the period. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Stock Up 0.9 %

Shares of VanEck Biotech ETF stock traded up $1.58 on Friday, reaching $177.14. The company’s stock had a trading volume of 1,787 shares, compared to its average volume of 6,918. The stock has a 50-day moving average price of $178.11 and a 200-day moving average price of $170.64. VanEck Biotech ETF has a 52-week low of $142.51 and a 52-week high of $183.64.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.